Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could lavender oil ease PTSD? new trial aims to find out

NCT ID NCT06412757

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether Silexan, a lavender oil extract available over-the-counter, can reduce PTSD symptoms in adults. 278 participants will take Silexan or a placebo daily for 12 weeks alongside their usual treatments. The goal is to see if this well-tolerated supplement offers a new option for those who struggle with current therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Silexan (lavender oil extract)
What this could lead to
If it works, this could provide a well-tolerated, over-the-counter option to ease PTSD symptoms for adults.
What could go wrong
This is a Phase 3 trial, but previous evidence is limited to a small pilot study. The effect may be small or no better than placebo. Mild side effects like burping or breath odour are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 278 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years or over. 2. Fluent in English. 3. Meet DSM-5 criteria for PTSD, irrespective of occupation (e.g. first responder, police officer, ex-military or civilian), determined using the Mini International Neuropsychiatric Interview 7.0.2. 4. Have a score on the PTSD Checklist for DSM-5 (PCL-5) equal to or over 33. Exclusion Criteria: 1. Are currently serving in the Australian Defence Force 2. Lifetime history of a psychotic or bipolar disorder, or dissociative identity disorder. 3. Moderate or severe alcohol or other substance use disorder within 3 months of screening. 4. Active suicidal or homicidal ideation. 5. Borderline Personality Disorder (BPD). 6. Acute or unstable medical illness or other significant medical condition, that would make participation in the trial unsafe or inappropriate. 7. Pregnancy, lactation or unwillingness to use an acceptable method of contraception (required for both males and females who are of reproductive potential and sexually active with partners of the opposite sex) through the duration of participants' involvement in the study up to and including week 16. Participants will also be advised not to donate eggs or sperm during the study period. 8. Commencement of a trauma-focussed psychotherapy (including Prolonged Exposure, Cognitive Processing Therapy and Eye Movement Desensitisation and Reprocessing) within 3 months of screening. 9. Commencement or change in dose of psychoactive medications within 4 weeks of screening. 10. Participants will be asked not to initiate psychotherapy or change the dose of psychoactive medications during the course of the study except in clinically urgent circumstances; if this becomes necessary, a decision will be made on a case-by-case basis with regard to retaining the participant or terminating their participation. 11. Severe acquired brain injury. 12. Individual is not eligible for public mental health services due to their visa status in Australia or for any other reason. 13. Any other condition that in the opinion of the research team is likely to make completion of the trial requirements infeasible. 14. Inability to understand or speak English to the extent necessary to give informed consent and complete the trial (researcher or clinician-determined).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-traumatic stress disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • Deakin University

    RECRUITING

    Geelong, Victoria, 3220, Australia

  • Ramsay Clinic Albert Road

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • University of Melbourne

    RECRUITING

    Carlton, Victoria, 5053, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.